Float Short %

15.76

Margin Of Safety %

-14

Put/Call OI Ratio

0.23

EPS Next Q Diff

-2.19

EPS Last/This Y

1.87

EPS This/Next Y

-1.42

Price

23.79

Target Price

35.39

Analyst Recom

Performance Q

-11.36

Relative Volume

1.19

Beta

0.31

Ticker: APLS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	APLS	19.01	0.19	0.89	61670
2025-11-11	APLS	19.51	0.20	0.54	62151
2025-11-12	APLS	19.94	0.20	6.64	62166
2025-11-13	APLS	19.83	0.22	0.18	63296
2025-11-14	APLS	20.33	0.22	0.68	63736
2025-11-17	APLS	20.09	0.22	0.44	63768
2025-11-18	APLS	19.73	0.22	0.43	63783
2025-11-19	APLS	19.45	0.22	0.94	63692
2025-11-20	APLS	19.5	0.22	0.36	63672
2025-11-21	APLS	19.61	0.20	1.68	62893
2025-11-24	APLS	20.13	0.19	0.16	58071
2025-11-25	APLS	21.01	0.19	0.15	58267
2025-11-26	APLS	21.58	0.19	0.11	58489
2025-12-01	APLS	21.2	0.18	0.04	58910
2025-12-02	APLS	20.68	0.18	0.67	58911
2025-12-03	APLS	21.25	0.19	0.00	58966
2025-12-04	APLS	22.2	0.19	0.13	58725
2025-12-05	APLS	23.61	0.19	5.32	58826
2025-12-08	APLS	23.79	0.23	3.85	60996
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	APLS	19.00	-33.5	-224.8	-0.17
2025-11-11	APLS	19.51	-32.6	-230.2	0.27
2025-11-12	APLS	20.02	-32.6	-230.2	0.27
2025-11-13	APLS	19.83	-32.6	-225.4	0.27
2025-11-14	APLS	20.33	-32.6	-230.1	0.27
2025-11-17	APLS	20.09	-32.6	-225.1	0.27
2025-11-18	APLS	19.73	-32.6	-224.2	0.27
2025-11-19	APLS	19.45	-32.6	-224.8	0.27
2025-11-20	APLS	19.55	-32.6	-227.3	0.27
2025-11-21	APLS	19.61	-32.6	-227.2	0.27
2025-11-24	APLS	20.13	-32.6	-230.3	0.27
2025-11-25	APLS	21.00	-32.6	-232.6	0.27
2025-11-26	APLS	21.57	-32.6	-230.3	0.27
2025-12-01	APLS	21.18	-32.6	-225.9	0.27
2025-12-02	APLS	20.66	-32.6	-223.2	0.27
2025-12-03	APLS	21.25	-32.6	-230.5	0.27
2025-12-04	APLS	22.19	-32.6	-232.7	0.27
2025-12-05	APLS	23.63	-32.6	-235.4	0.27
2025-12-08	APLS	23.79	-32.6	-	0.27
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	APLS	-2.56	2.96	17.27
2025-11-11	APLS	-2.56	2.96	17.27
2025-11-12	APLS	-2.56	2.96	14.54
2025-11-13	APLS	-2.56	2.96	14.54
2025-11-14	APLS	-2.56	2.96	14.54
2025-11-17	APLS	-2.56	16.19	14.54
2025-11-18	APLS	-2.58	16.19	14.54
2025-11-19	APLS	-2.58	16.19	14.54
2025-11-20	APLS	-2.58	16.19	14.54
2025-11-21	APLS	-2.58	16.19	14.66
2025-11-24	APLS	-2.49	-2.36	14.66
2025-11-25	APLS	-2.49	-2.36	14.66
2025-11-26	APLS	-2.49	-2.36	15.76
2025-12-01	APLS	-2.49	-2.36	15.76
2025-12-02	APLS	-2.49	-2.36	15.76
2025-12-03	APLS	-2.49	-2.36	15.76
2025-12-04	APLS	-2.49	-2.36	15.76
2025-12-05	APLS	-2.49	-2.36	15.76
2025-12-08	APLS	-2.49	-2.36	15.76
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

1.67

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.52

Insider Transactions

-2.49

Institutional Transactions

-2.36

Beta

0.31

Average Sales Estimate Current Quarter

201

Average Sales Estimate Next Quarter

193

Fair Value

20.43

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

74.9

Max Drawdown 5-Year %

-82.5

Target Price

35.39

P/E

80.13

Forward P/E

PEG

1.23

P/S

2.96

P/B

7.5

P/Free Cash Flow

38.28

EPS

0.3

Average EPS Est. Cur. Y

0.27

EPS Next Y. (Est.)

-1.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.43

Relative Volume

1.19

Return on Equity vs Sector %

-15.7

Return on Equity vs Industry %

-0.7

EPS 1 7Days Diff

0.6

EPS 1 30Days Diff

0.53

EBIT Estimation

Apellis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 705

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today

news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance

stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market

stock prices APLS premarket after hours

ticker APLS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: APLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y